£300K
The Cambridge-based biotechnology company secured the capital from a group of angel investors and Finance Wales.
Nemesis Bioscience develops biological therapeutics to suppress antibiotic resistance.
Nemesis Bioscience is a biotechnology company developing therapeutics to tackle antibiotic resistance.
Cash at bank
Net current assets
Total assets less current liabilities
Net assets
Shareholders' funds
Fixed assets
Cash, assets and headcount from Nemesis Bioscience's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Frank Massam
Chief executive
The Cambridge-based biotechnology company secured the capital from a group of angel investors and Finance Wales.